Skip to main content

Mahoney Michael F's Form 4 filing

Boston Scientific Corp (BSX) · filed Feb 3, 2026

Accession no.
0001225208-26-001156
Filed
Feb 3, 2026
Trade date
Feb 2, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $15.0M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahoney Michael FCIK 0001533022Director, Officer (Chairman, President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 2, 2026Common StockMOption exerciseAcquired+49,407$24.55+$1,212,941.851,526,289Direct
Feb 2, 2026Common StockMOption exerciseAcquired+46,347$27.09+$1,255,540.231,572,636Direct
Feb 2, 2026Common StockSSaleDisposed−1,200$94.06F2−$112,8721,571,436Direct
Feb 2, 2026Common StockSSaleDisposed−159,701$93.49F3−$14,930,446.491,411,735Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 2, 2026Common StockMOption exerciseDisposed−46,347$0.00$0231,739Direct
Feb 2, 2026Common StockMOption exerciseDisposed−49,407$0.00$098,814Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.985, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)